JPM26: Eli Lilly's obesity drugs target commercial and governmental access [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
is going head-to-head with Trulicity (dulaglutide). Eli Lilly's patient access program, LillyDirect, served over one million patients a month in 2025, allowing patients to access certified obesity experts via telehealth, with online pharmacy service options available, knowing exact prices before payment. With supply issues resolved, the company has established new commercial and governmental pathways to ensure weight-loss and obesity novel therapies are more accessible to patients, ultimately improving patient outcomes. At the 44th Annual JP Morgan Healthcare Conference, Eli Lilly highlighted its viewpoint for expanding access within the obesity market at the conference in San Francisco, California, on 13 January 2026. Eli Lilly's tirzepatide, branded as Mounjaro and Zepbound, was initially indicated for patients with type 2 diabetes (T2D) and obesity, respectively. GlobalData's Sales and Forecast Database forecasts that tirzepatide generate over $64bn by 2031. Furthermore, the SURP
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- This Company Is Doubling Down on AI. Is the Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch [CNBC]CNBC
- Eli Lilly: Exceptional 2025, But Rising Headwinds Loom In 2026 [Seeking Alpha]Seeking Alpha
- Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Jefferies Financial Group Inc. from $976.00 to $1,300.00. They now have a "buy" rating on the stock.MarketBeat
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- LLY's page on the SEC website